Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487

1.

Cardiovascular Event Risk in Rheumatoid Arthritis is Higher than in Type 2 Diabetes: a 15 Year Longitudinal Study.

Agca R, Hopman LHGA, Laan KCJ, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
2.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
3.

An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis.

Luís M, Freitas J, Costa F, Buttgereit F, Boers M, Jap DS, Santiago T.

Expert Opin Drug Saf. 2019 May 6:1-10. doi: 10.1080/14740338.2019.1615052. [Epub ahead of print]

PMID:
31056959
4.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 May 1. pii: jrheum.190196. doi: 10.3899/jrheum.190196. [Epub ahead of print]

PMID:
31043547
5.

Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data.

Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M.

Semin Arthritis Rheum. 2019 Feb 21. pii: S0049-0172(18)30507-9. doi: 10.1016/j.semarthrit.2019.02.009. [Epub ahead of print] Review.

PMID:
30878153
6.

The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example.

Terslev L, Naredo E, Keen HI, Bruyn GAW, Iagnocco A, Wakefield RJ, Conaghan PG, Maxwell LJ, Beaton DE, Boers M, D'Agostino MA.

J Rheumatol. 2019 Mar 15. pii: jrheum.181158. doi: 10.3899/jrheum.181158. [Epub ahead of print]

PMID:
30877208
7.

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.

Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Mar 1. pii: jrheum.181066. doi: 10.3899/jrheum.181066. [Epub ahead of print]

PMID:
30824657
8.

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.

Poppelaars PB, van Tuyl LHD, Boers M.

Ann Rheum Dis. 2019 May;78(5):586-589. doi: 10.1136/annrheumdis-2018-214618. Epub 2019 Feb 26.

PMID:
30808623
9.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181096. doi: 10.3899/jrheum.181096. [Epub ahead of print]

PMID:
30770515
10.

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam LS, Choy EH.

J Rheumatol. 2019 Feb 15. pii: jrheum.181054. doi: 10.3899/jrheum.181054. [Epub ahead of print]

PMID:
30770514
11.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181097. doi: 10.3899/jrheum.181097. [Epub ahead of print]

PMID:
30770502
12.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 1. pii: jrheum.181218. doi: 10.3899/jrheum.181218. [Epub ahead of print]

PMID:
30709952
13.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
14.

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Dodd S, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Jan 15. pii: jrheum.181194. doi: 10.3899/jrheum.181194. [Epub ahead of print]

PMID:
30647185
15.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
16.

Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people.

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, Buttgereit F.

Semin Arthritis Rheum. 2018 Nov 2. pii: S0049-0172(18)30487-6. doi: 10.1016/j.semarthrit.2018.10.017. [Epub ahead of print]

PMID:
30466715
17.

Effects of Co-medication with Glucocorticoids in Biologics Trials.

Boers M.

J Rheumatol. 2018 Nov;45(11):1605. doi: 10.3899/jrheum.180151. Epub 2018 Nov 1. No abstract available.

PMID:
30385699
18.

Validation of two PROMIS item banks for measuring social participation in the Dutch general population.

Terwee CB, Crins MHP, Boers M, de Vet HCW, Roorda LD.

Qual Life Res. 2019 Jan;28(1):211-220. doi: 10.1007/s11136-018-1995-0. Epub 2018 Sep 10.

19.

Outcome measures for adherence data from a medication event monitoring system: A literature review.

Hartman L, Lems WF, Boers M.

J Clin Pharm Ther. 2019 Feb;44(1):1-5. doi: 10.1111/jcpt.12757. Epub 2018 Sep 1. Review.

PMID:
30171815
20.

Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review.

Chiarotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB.

J Pain. 2019 Mar;20(3):245-263. doi: 10.1016/j.jpain.2018.07.009. Epub 2018 Aug 10. Review.

PMID:
30099210
21.

Excessive Pricing Causes Poor Access to Biologics.

Boers M.

J Rheumatol. 2018 Jun;45(6):876. doi: 10.3899/jrheum.171401. No abstract available.

PMID:
29858458
22.

Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review.

Chiarotto A, Terwee CB, Kamper SJ, Boers M, Ostelo RW.

J Clin Epidemiol. 2018 Oct;102:23-37. doi: 10.1016/j.jclinepi.2018.05.006. Epub 2018 May 21. Review.

PMID:
29793009
23.

Evaluation of the wear-and-tear scale for therapeutic footwear, results of a generalizability study.

Dahmen R, Siemonsma PC, Monteiro S, Norman GR, Boers M, Lankhorst GJ, Roorda LD.

J Rehabil Med. 2018 Jun 15;50(6):569-574. doi: 10.2340/16501977-2339.

24.

Designing effective graphs to get your message across.

Boers M.

Ann Rheum Dis. 2018 Jun;77(6):833-839. doi: 10.1136/annrheumdis-2018-213396. Review. Erratum in: Ann Rheum Dis. 2019 Mar;78(3):442.

PMID:
29748338
25.

A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.

Boers M, Singh JA, Cofield SS, Bridges SL Jr, Moreland LW, O'Dell JR, Wu H, Leatherman S, Curtis JR.

Arthritis Care Res (Hoboken). 2019 Feb;71(2):319-322. doi: 10.1002/acr.23590. Epub 2019 Jan 10.

PMID:
29691998
26.

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, Simpson E, Gerbens LAA, Boers M, Barbarot S, Stalder JF, Abuabara K, Aoki V, Ardeleanu M, Armstrong J, Bang B, Berents TL, Burton T, Butler L, Chubachi T, Cresswell-Melville A, DeLozier A, Eckert L, Eichenfield L, Flohr C, Futamura M, Gadkari A, Gjerde ES, van Halewijn KF, Hawkes C, Howells L, Howie L, Humphreys R, Ishii HA, Kataoka Y, Katayama I, Kouwenhoven W, Langan SM, Leshem YA, Merhand S, Mina-Osorio P, Murota H, Nakahara T, Nunes FP, Nygaard U, Nygårdas M, Ohya Y, Ono E, Rehbinder E, Rogers NK, Romeijn GLE, Schuttelaar MLA, Sears AV, Simpson MA, Singh JA, Srour J, Stuart B, Svensson Å, Talmo G, Talmo H, Teixeira HD, Thyssen JP, Todd G, Torchet F, Volke A, von Kobyletzki L, Weisshaar E, Wollenberg A, Zaniboni M.

Br J Dermatol. 2018 May;178(5):e332-e341. doi: 10.1111/bjd.16543. Epub 2018 Apr 19.

PMID:
29672835
27.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

28.

The controversy of using PGA to define remission in RA.

van Tuyl LHD, Boers M.

Nat Rev Rheumatol. 2018 Mar 21;14(4):245. doi: 10.1038/nrrheum.2018.36. No abstract available.

PMID:
29559715
29.

Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.

Britsemmer K, van Schaardenburg D, Boers M, De Cock D, Verschueren P, Radner H, Smolen JS, van Tuyl LHD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):362-370. Epub 2018 Feb 26.

PMID:
29533752
30.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

31.

Core outcome measurement instruments for clinical trials in nonspecific low back pain.

Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LOP, Foster NE, Grotle M, Koes BW, Kovacs FM, Lin CC, Maher CG, Pearson AM, Peul WC, Schoene ML, Turk DC, van Tulder MW, Terwee CB, Ostelo RW.

Pain. 2018 Mar;159(3):481-495. doi: 10.1097/j.pain.0000000000001117.

32.

A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain.

Chiarotto A, Ostelo RW, Boers M, Terwee CB.

J Clin Epidemiol. 2018 Mar;95:73-93. doi: 10.1016/j.jclinepi.2017.11.005. Epub 2017 Nov 14. Review.

PMID:
29154811
33.

More erronous statements about the use of frequentist statistical methods in medical research.

Boers M.

Clin Exp Rheumatol. 2017 Oct 26. [Epub ahead of print] No abstract available.

PMID:
29148414
34.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475
35.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

36.

Reply.

Palmowski Y, Buttgereit F, Boers M.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):577-578. doi: 10.1002/acr.23452. No abstract available.

PMID:
29073333
37.

Graphics and statistics for cardiology: designing effective tables for presentation and publication.

Boers M.

Heart. 2018 Feb;104(3):192-200. doi: 10.1136/heartjnl-2017-311581. Epub 2017 Oct 13. Review.

PMID:
29030423
38.

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.

Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, Hoekstra T.

Rheumatology (Oxford). 2018 Mar 1;57(3):555-562. doi: 10.1093/rheumatology/kex338. Review.

PMID:
29029294
39.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
40.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
41.

Rheumatoid arthritis: Remission - keeping the patient experience front and centre.

van Tuyl LHD, Boers M.

Nat Rev Rheumatol. 2017 Oct;13(10):573-574. doi: 10.1038/nrrheum.2017.139. Epub 2017 Aug 31. No abstract available.

PMID:
28855692
42.

Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016.

Rasch LA, Boers M, Hill CL, Voshaar M, Hoogland W, de Wit M, Flurey C, Davis B, Hetland ML, Brahe CH, Gossec L, Wells GA, Tugwell P, Kuriya B, Goel N, Singh JA, Duarte C, Da Silva J, van Schaardenburg D, Proudman S, van Tuyl LHD; Working Group on the Patients’ Perspective on Remission in Rheumatoid Arthritis.

J Rheumatol. 2017 Dec;44(12):1889-1893. doi: 10.3899/jrheum.161111. Epub 2017 Aug 1.

PMID:
28765250
43.

Influence of timing of delayed hard palate closure on articulation skills in 3-year-old Danish children with unilateral cleft lip and palate.

Willadsen E, Boers M, Schöps A, Kisling-Møller M, Nielsen JB, Jørgensen LD, Andersen M, Bolund S, Andersen HS.

Int J Lang Commun Disord. 2018 Jan;53(1):130-143. doi: 10.1111/1460-6984.12331. Epub 2017 Jul 25.

PMID:
28741729
44.

Core outcome sets for research and clinical practice.

Chiarotto A, Ostelo RW, Turk DC, Buchbinder R, Boers M.

Braz J Phys Ther. 2017 Mar - Apr;21(2):77-84. doi: 10.1016/j.bjpt.2017.03.001. Epub 2017 Mar 18. Review.

45.

Observational studies on glucocorticoids are harmful!

Boers M.

Lupus Sci Med. 2017 Apr 7;4(1):e000219. doi: 10.1136/lupus-2017-000219. eCollection 2017. No abstract available.

46.

The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain.

Crins MHP, Terwee CB, Klausch T, Smits N, de Vet HCW, Westhovens R, Cella D, Cook KF, Revicki DA, van Leeuwen J, Boers M, Dekker J, Roorda LD.

J Clin Epidemiol. 2017 Jul;87:47-58. doi: 10.1016/j.jclinepi.2017.03.011. Epub 2017 Mar 28.

PMID:
28363734
47.

Validity of auditory perceptual assessment of velopharyngeal function and dysfunction - the VPC-Sum and the VPC-Rate.

Lohmander A, Hagberg E, Persson C, Willadsen E, Lundeborg I, Davies J, Havstam C, Boers M, Kisling-Møller M, Alaluusua S, Aukner R, Pedersen NH, Turunen L, Nyberg J.

Clin Linguist Phon. 2017;31(7-9):589-597. doi: 10.1080/02699206.2017.1302510. Epub 2017 Mar 31.

PMID:
28362219
48.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

49.

A Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 1. Planning and management.

Semb G, Enemark H, Friede H, Paulin G, Lilja J, Rautio J, Andersen M, Åbyholm F, Lohmander A, Shaw W, Mølsted K, Heliövaara A, Bolund S, Hukki J, Vindenes H, Davenport P, Arctander K, Larson O, Berggren A, Whitby D, Leonard A, Neovius E, Elander A, Willadsen E, Bannister RP, Bradbury E, Henningsson G, Persson C, Eyres P, Emborg B, Kisling-Møller M, Küseler A, Granhof Black B, Schöps A, Bau A, Boers M, Andersen HS, Jeppesen K, Marxen D, Paaso M, Hölttä E, Alaluusua S, Turunen L, Humerinta K, Elfving-Little U, Tørdal IB, Kjøll L, Aukner R, Hide Ø, Feragen KB, Rønning E, Skaare P, Brinck E, Semmingsen AM, Lindberg N, Bowden M, Davies J, Mooney J, Bellardie H, Schofield N, Nyberg J, Lundberg M, Karsten AL, Larson M, Holmefjord A, Reisæter S, Pedersen NH, Rasmussen T, Tindlund R, Sæle P, Blomhoff R, Jacobsen G, Havstam C, Rizell S, Enocson L, Hagberg C, Najar Chalien M, Paganini A, Lundeborg I, Marcusson A, Mjönes AB, Gustavsson A, Hayden C, McAleer E, Slevan E, Gregg T, Worthington H.

J Plast Surg Hand Surg. 2017 Feb;51(1):2-13. doi: 10.1080/2000656X.2016.1263202. Review.

PMID:
28218559
50.

Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 5. Speech outcomes in 5-year-olds - consonant proficiency and errors.

Willadsen E, Lohmander A, Persson C, Lundeborg I, Alaluusua S, Aukner R, Bau A, Boers M, Bowden M, Davies J, Emborg B, Havstam C, Hayden C, Henningsson G, Holmefjord A, Hölttä E, Kisling-Møller M, Kjøll L, Lundberg M, McAleer E, Nyberg J, Paaso M, Pedersen NH, Rasmussen T, Reisæter S, Andersen HS, Schöps A, Tørdal IB, Semb G.

J Plast Surg Hand Surg. 2017 Feb;51(1):38-51. doi: 10.1080/2000656X.2016.1254647. Review.

PMID:
28218556

Supplemental Content

Support Center